This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What's in Store for Vertex in 2020 After a Remarkable 2019?
by Kinjel Shah
In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.
J&J (JNJ) Signs Deal With HHS to Develop Coronavirus Vaccine
by Zacks Equity Research
Johnson & Johnson (JNJ) expands its agreement with BARDA, part of U.S. Department of Health and Human Services for accelerated development of a vaccine for the newly found coronavirus.
Inovio Gets FDA Nod to Begin Study on INO-3107, Stock Gains
by Zacks Equity Research
The FDA accepts Inovio's (INO) IND application for INO-3107 to initiate a phase I/II study for the treatment of recurrent respiratory papillomatosis, a rare disease caused by HPV. Stock up.
Can Biotech ETFs Continue to Soar in 2020?
by Neena Mishra
We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.
Should Growth Investors Buy this Cancer Screening Biotech Stock?
by Benjamin Rains
Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $20.38 in the latest trading session, marking a -0.63% move from the prior day.
J&J (JNJ) Plans to Develop Vaccine for New Coronavirus
by Zacks Equity Research
J&J (JNJ) is looking to develop a vaccine for the new coronavirus infection. Its drug Erleada's label is expanded to include new prostate cancer patient population in Europe.
Coronavirus: How Fast to 100,000 Infected?
by Kevin Cook
The current geometric rate of transmission implies that over 100,000 people could be infected by early February.
Coronavirus: Epidemic or Pandemic?
by Kevin Cook
The current geometric rate of transmission implies that over 100,000 people could be infected by early February.
Implied Volatility Surging for Moderna (MRNA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
Wining & Losing ETF Areas on Coronavirus Outbreak
by Sanghamitra Saha
Coronavirus outbreak puts these ETF areas in winning and losing positions.
Coronavirus Spooks Global Markets: Winners and Losers
by Zacks Equity Research
So far, 18 fatalities and more than 600 are affected by coronavirus in China and the virus is spreading across the boundary, spooking investors.
CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs
by Indrajit Bandyopadhyay
Several public and private organizations are coming forward to develop vaccines for the new coronavirus by funding developmental programs.
Company News for Jan 23, 2020
by Zacks Equity Research
Companies in the news are: FSB, AKCA, ALLY, MRNA
3 Biotech Stocks Likely to Gain as Coronavirus Spreads
by Zacks Equity Research
Here we discuss three biotech stocks, which are likely to benefit in case there is an outbreak of coronavirus infection in China.
Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
5 Biotech Stocks Set for Continued Rally in 2020
by Zacks Equity Research
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
The Zacks Analyst Blog Highlights: Alteryx, Moderna, Car-Mart, Bloom Energy and Target
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alteryx, Moderna, Car-Mart, Bloom Energy and Target
5 Top Stocks That Surged Amid Volatility in the Last 7 Days
by Nalak Das
Volatility has gripped Wall Street since the past week owing to several conflicting news about the signing of an interim trade deal between the United States and China.
Moderna, Inc. (MRNA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Moderna, Inc. (MRNA).
Top Ranked Momentum Stocks to Buy for November 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 8th
Moderna (MRNA) Jumps: Stock Rises 5.6%
by Zacks Equity Research
Moderna (MRNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Options Traders Expect Huge Moves in Moderna (MRNA) Stock
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
Why Earnings Season Could Be Great for Moderna (MRNA)
by Zacks Equity Research
Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
by Ekta Bagri
We take a look at companies, which have been developing treatments for various diseases using RNAi technology.